Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation

Leuk Lymphoma. 2018 Nov;59(11):2755-2756. doi: 10.1080/10428194.2018.1443335. Epub 2018 Apr 12.

Authors

Tomomi Takei¹, Kazuaki Yokoyama², Eigo Shimizu³, Takaaki Konuma², Satoshi Takahashi², Rui Yamaguchi³, Seiya Imoto⁴, Satoru Miyano³, Arinobu Tojo¹

Affiliations

¹ a Division of Molecular Therapy, Advanced Clinical Research Center, the Institute of Medical Science , University of Tokyo , Tokyo , Japan.
² b Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science , University of Tokyo , Tokyo , Japan.
³ c Laboratory of DNA Information Analysis, Human Genome Center , Institute of Medical Science, University of Tokyo , Tokyo , Japan.
⁴ d Division of Health Medical Data Science, Health Intelligence Center , Institute of Medical Science, University of Tokyo , Tokyo , Japan.

PMID: 29648492
DOI: 10.1080/10428194.2018.1443335

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antimetabolites, Antineoplastic / therapeutic use
Azacitidine / therapeutic use*
Cord Blood Stem Cell Transplantation / adverse effects*
Humans
Leukemia, Myeloid, Acute / complications
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Male
Mutation*
Myelodysplastic Syndromes / complications
Myelodysplastic Syndromes / genetics
Myelodysplastic Syndromes / pathology
Myelodysplastic Syndromes / therapy*
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / etiology
Neoplasm Recurrence, Local / pathology
Neoplasms, Second Primary / drug therapy*
Neoplasms, Second Primary / etiology
Neoplasms, Second Primary / pathology
Prognosis
Salvage Therapy
Tumor Suppressor Protein p53 / genetics*

Substances

Antimetabolites, Antineoplastic
TP53 protein, human
Tumor Suppressor Protein p53
Azacitidine